Tumor Agnostic Education Center Disease State Hub

Tumor Agnostic

Education Center

News

Adjuvant Dabrafenib Plus Trametinib Improved Long-Term Survival Among Patients With Advanced-Stage Melanoma Harboring BRAF V600 Mutations

07/11/2024

Stephanie Holland ;

According to final analysis results from the phase 3 COMBI-AD trial, adjuvant dabrafenib plus trametinib improved long-term recurrence-free and distant metastasis-free survival compared to placebo among patients with stage 3 melanoma...

According to final analysis...

07/11/2024

Oncology

News

Addition of Targeted Therapy Induction Phase to Combined Immunotherapy for Patients with BRAF-V600E/K Mutant Melanoma

06/20/2024

Allison Casey

According to a phase 2 study, there was no difference in PFS between a combined immunotherapy regimen and a targeted therapy induction followed by combined immunotherapy among patients with BRAF/V600E/K mutant melanoma.

According to a phase 2 study,...

06/20/2024

Oncology

Rebecca Heist, MD, MPH, Massachusetts General Hospital

Conference Coverage

Targeted Therapies for Patients With Lung Cancer Exhibiting BRAF Mutations or MET Skipping Alterations

05/02/2024

Featuring Rebecca Heist, MD, MPH

Featuring Rebecca Heist, MD, MPH ...

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Rebecca Heist, MD, MPH, debated in favor of using targeted therapy for patients with lung cancer who exhibit BRAF mutations or MET exon 14 skipping alterations.

At the Great Debates and Updates...

05/02/2024

Oncology

News

FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

04/25/2024

Stephanie Holland

Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...

Based on results from the...

04/25/2024

Oncology

News

‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma

02/21/2024

Stephanie Holland

Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...

Study results demonstrated that...

02/21/2024

Oncology

News

FDA Approves Encorafenib Plus Binimetinib for Metastatic BRAF V600E Non-Small Cell Lung Cancer

10/12/2023

Stephanie Holland

Based on findings from the PHAROS trial, the FDA has approved encorafenib plus binimetinib for adult patients with metastatic non-small cell lung cancer harboring a BRAF V600E mutation.

Based on findings from the...

10/12/2023

Oncology

Videos

Management of BRAF-Mutated Non-Small Cell Lung Cancer

09/26/2023

Featuring Lyudmila Bazhenova, MD

Featuring Lyudmila Bazhenova, MD ...

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Lyudmila Bazhenova, MD, discussed developments and advances in the management of BRAF-mutated NSCLC.

At the Great Debates & Updates...

09/26/2023

Oncology

News

Addition of Binimetinib to Encorafenib Demonstrated Efficacy, Safety Among Patients With Advanced, Unresectable BRAFV600-Mutant Melanoma

09/11/2023

Stephanie Holland

According to results from part 2 of the phase 3 COLUMBUS trial, the addition of binimetinib to encorafenib improved progression-free survival, overall response rate, and had a favorable safety profile compared with encorafenib alone among...

According to results from part 2...

09/11/2023

Oncology

Josep Tabernero, MD, PhD, Vall d'Hebron Barcelona Hospital Campus

Videos

Sequencing of Encorafenib Plus Cetuximab Among Patients With BRAF-Mutant Metastatic Colorectal Cancer

08/25/2023

Featuring Josep Tabernero, MD, PhD

Featuring Josep Tabernero, MD, PhD ...

At the 2023 World Congress on Gastrointestinal Cancers, Josep Tabernero, MD, PhD presented a post hoc analysis of the BEACON trial that evaluated differences among patients with BRAF V600E-mutant metastatic colorectal cancer treated with...

At the 2023 World Congress on...

08/25/2023

Oncology

Conference Coverage

Navitoclax Added to Dabrafenib-Trametinib Improved Response, Survival Among Patients With BRAF-Mutant Metastatic Melanoma

06/12/2023

Stephanie Holland

Findings of a phase 2 study presented at the 2023 ASCO Annual Meeting demonstrated the addition of navitoclax to dabrafenib and trametinib improved response and survival outcomes for patients with BRAF-mutant metastatic melanoma.

Findings of a phase 2 study...

06/12/2023

Oncology

Recent News

News

Adjuvant Dabrafenib Plus Trametinib Improved Long-Term Survival Among Patients With Advanced-Stage Melanoma Harboring BRAF V600 Mutations

07/11/2024

Stephanie Holland ;

According to final analysis...

07/11/2024

Oncology

News

Addition of Targeted Therapy Induction Phase to Combined Immunotherapy for Patients with BRAF-V600E/K Mutant Melanoma

06/20/2024

Allison Casey

According to a phase 2 study,...

06/20/2024

Oncology

News

FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

04/25/2024

Stephanie Holland

Based on results from the...

04/25/2024

Oncology

News

‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma

02/21/2024

Stephanie Holland

Study results demonstrated that...

02/21/2024

Oncology

News

FDA Approves Encorafenib Plus Binimetinib for Metastatic BRAF V600E Non-Small Cell Lung Cancer

10/12/2023

Stephanie Holland

Based on findings from the PHAROS trial, the FDA has approved encorafenib plus binimetinib for adult patients with metastatic non-small cell lung cancer harboring a BRAF V600E mutation.

Based on findings from the...

10/12/2023

Oncology

News

Addition of Binimetinib to Encorafenib Demonstrated Efficacy, Safety Among Patients With Advanced, Unresectable BRAFV600-Mutant Melanoma

09/11/2023

Stephanie Holland

According to results from part 2...

09/11/2023

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology